Digital Pharma is running out of names. Can an AI help? At Reuters Pharma USA, presenters showed off an AI aimed at reimagining the complex process of pharmaceutical naming.
News Regeneron tries again with lymphoma bispecific in US Regeneron has refiled its CD20xCD3 bispecific odronextamab for lymphoma with the FDA, which was rejected last year, but is seeking a narrower label.
News Evidence builds behind Regeneron's deafness gene therapy Ten out of 11 children with congenital deafness treated with a gene therapy developed by Regeneron have seen "notable" improvements in hearing.
News Can Dupixent plug treatment gap in bullous pemphigoid? The FDA is scheduled to deliver a verdict on Sanofi and Regeneron's Dupixent for rare autoimmune skin disorder bullous pemphigoid in June.
News Regeneron, Illumina join $320m Truveta investment Regeneron and Illumina have joined a major investment in health data specialist Truveta that will support the creation of a major new genome project.
News Regeneron builds in eye disease tech with Oxular takeover Regeneron has bought Oxular, a UK specialist in retinal diseases, in a move that bolsters its already strong position in ophthalmology therapies.
News Lilly throws lifeline to Sangamo with $1.4bn licensing deal A $1.4 billion gene therapy alliance with Eli Lilly has come at an opportune time for Sangamo as its cash reserves start to dry up.
Sales & Marketing Sponsored Health Trends 2025: Reimagining What's Possible Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl
